ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) | Zendy

Rajesh Pahwa | Zendy; Caroline M. Tanner | Zendy; Robert A. Hauser | Zendy; Stuart Isaacson | Zendy; Paul A. Nausieda | Zendy; Daniel Truong | Zendy; Pinky Agarwal | Zendy; Keith L. Hull | Zendy; Kelly E. Lyons | Zendy; Reed Johnson | Zendy; Mary Jean Stempien | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)

Author(s) -

Rajesh Pahwa,

Caroline M. Tanner,

Robert A. Hauser,

Stuart Isaacson,

Paul A. Nausieda,

Daniel Truong,

Pinky Agarwal,

Keith L. Hull,

Kelly E. Lyons,

Reed Johnson,

Mary Jean Stempien

Publication year - 2017

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2017.0943

Subject(s) - medicine , placebo , dyskinesia , bedtime , population , levodopa , amantadine , randomized controlled trial , rating scale , anesthesia , disease , parkinson's disease , pharmacology , alternative medicine , environmental health , pathology , psychology , developmental psychology

Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research